Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Kennedy
Simon Pickard
Jean-Eric Tarride
Feng Xie

Showing results (1-10 of 2,089) with videos related to

Pageof 209
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 14, 2023
Resurrecting Multiattribute Utility Function: Developing a Value Set for Health Utility for GlaucomaKevin Kennedy, Simon Pickard, Jean-Eric Tarride, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 27, 2024
Systematic methodological review of health state values in glaucoma cost-utility analysesKevin Kennedy, Gurkaran Sarohia, Dominik Podbielski, et al.
Pharmacoeconomics - Open|February 22, 2018
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in CanadaGraeme Ball, Feng Xie, Jean-Eric Tarride
Clinicoeconomics and Outcomes Research : CEOR|December 13, 2018
A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissionsNaghmeh Foroutan, Jean-Eric Tarride, Feng Xie, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 10, 2011
Calculating utility decrements associated with an adverse event: marginal Tobit and CLAD coefficients should be used with cautionEleanor M Pullenayegum, Jean-Eric Tarride, Feng Xie, et al.
Pharmacoeconomics - Open|May 2, 2019
A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private PayersNaghmeh Foroutan, Jean-Eric Tarride, Feng Xie, et al.
Hospital Practice (1995)|May 23, 2012
Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi studyFeng Xie, Rob Hopkins, Natasha Burke, et al.
International Journal of Circumpolar Health|September 20, 2011
Health economic evaluations help inform payers of the best use of scarce health care resourcesDaria O'Reilly, Kathryn Gaebel, Feng Xie, et al.
Genetic Testing and Molecular Biomarkers|September 27, 2012
Economic evaluations conducted for assessment of genetic testing technologies: a systematic reviewNazila Assasi, Lisa Schwartz, Jean-Eric Tarride, et al.
Current Oncology (Toronto, Ont.)|May 26, 2023
Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost-Utility Analysis from the Canadian Public Payer's PerspectiveFatemeh Mirzayeh Fashami, Mitchell Levine, Feng Xie, et al.
Pageof 209

Showing results (1-10 of 2,089) with videos related to

Sort By:
Pageof 209
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 14, 2023
Resurrecting Multiattribute Utility Function: Developing a Value Set for Health Utility for GlaucomaKevin Kennedy, Simon Pickard, Jean-Eric Tarride, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 27, 2024
Systematic methodological review of health state values in glaucoma cost-utility analysesKevin Kennedy, Gurkaran Sarohia, Dominik Podbielski, et al.
Pharmacoeconomics - Open|February 22, 2018
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in CanadaGraeme Ball, Feng Xie, Jean-Eric Tarride
Clinicoeconomics and Outcomes Research : CEOR|December 13, 2018
A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissionsNaghmeh Foroutan, Jean-Eric Tarride, Feng Xie, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 10, 2011
Calculating utility decrements associated with an adverse event: marginal Tobit and CLAD coefficients should be used with cautionEleanor M Pullenayegum, Jean-Eric Tarride, Feng Xie, et al.
Pharmacoeconomics - Open|May 2, 2019
A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private PayersNaghmeh Foroutan, Jean-Eric Tarride, Feng Xie, et al.
Hospital Practice (1995)|May 23, 2012
Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi studyFeng Xie, Rob Hopkins, Natasha Burke, et al.
International Journal of Circumpolar Health|September 20, 2011
Health economic evaluations help inform payers of the best use of scarce health care resourcesDaria O'Reilly, Kathryn Gaebel, Feng Xie, et al.
Genetic Testing and Molecular Biomarkers|September 27, 2012
Economic evaluations conducted for assessment of genetic testing technologies: a systematic reviewNazila Assasi, Lisa Schwartz, Jean-Eric Tarride, et al.
Current Oncology (Toronto, Ont.)|May 26, 2023
Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost-Utility Analysis from the Canadian Public Payer's PerspectiveFatemeh Mirzayeh Fashami, Mitchell Levine, Feng Xie, et al.
Pageof 209